Antihypertensive effect of Barnidipine (cas 104757-53-1) 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study
-
Add time:09/06/2019 Source:sciencedirect.com
Background: Dihydropyridine calcium antagonists are largely employed for the treatment of hypertension, coronary heart disease, and heart failure.Objective: The aim of our study was to compare the antihypertensive effect of the dihydropyridine calcium antagonists Barnidipine (cas 104757-53-1) and amlodipine.Methods: This was a 24-week, randomized, open-label, pilot study. Consecutive treatment-naive patients with grade I or II essential hypertension (office sitting systolic blood pressure [BP] of 140–179 mm Hg and diastolic BP of 90–109 mm Hg) were enrolled. The primary end points were the effect of treatment with either barnidipine 10 mg or amlodipine 5 mg once daily on office and ambulatory BP, left ventricular mass index (LVMI), and markers of cardiac damage, serum procollagen type I C-terminal propeptide, and plasma amino-terminal pro-B-type natriuretic peptide concentrations. Patients were assessed at enrollment, and 12 and 24 weeks. During each visit, the prevalence of adverse events (AEs) was also monitored using spontaneous reporting, patient interview, and physical examination, the relationship to study drug being determined by the investigators. Compliance with treatment was assessed at each study visit by counting returned tablets.Results: Thirty eligible patients (20 men, 10 women; mean [SD] age, 47 [12] years) were included in the study; all patients completed the 24 weeks of study treatment. Twelve weeks after randomization, 6 patients in the amlodipine group had their dose doubled to 10 mg due to inadequate BP control. Mean BP reductions at study end were not significantly different between the barnidipine and amlodipine groups (office BP, −10.3/−9.4 vs −16.6/−9.1 mm Hg; ambulatory BP, 9.4/6.4 vs 8.1/5.1 mm Hg). Reductions in LVMI and markers of cardiac damage were not significantly different between the 2 groups. Significantly more patients in the amlodipine group reported drug-related AEs compared with those in the barnidipine group (9 [60%] vs 2 [13%]; P < 0.05).Conclusion: In this small sample of treatment-naive hypertensive patients, the antihypertensive effect of barnidipine 10 mg once daily was not significantly different from that of amlodipine 5 to 10 mg once daily.
We also recommend Trading Suppliers and Manufacturers of Barnidipine (cas 104757-53-1). Pls Click Website Link as below: cas 104757-53-1 suppliers
Prev:Effects of Barnidipine (cas 104757-53-1) hydrochloride, a calcium channel blocker, on renal microcirculation in rats: a pilot study
Next:General paperHemodynamic effects of Barnidipine (cas 104757-53-1) hydrochloride in conscious squirrel monkeys) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- General paperHemodynamic effects of Barnidipine (cas 104757-53-1) hydrochloride in conscious squirrel monkeys09/07/2019
- Effects of Barnidipine (cas 104757-53-1) hydrochloride, a calcium channel blocker, on renal microcirculation in rats: a pilot study09/05/2019
- Sensitive and specific liquid chromatographic–tandem mass spectrometric assay for Barnidipine (cas 104757-53-1) in human plasma09/04/2019
- Antihypertensive efficacy and tolerability of Barnidipine (cas 104757-53-1) hydrochloride in patients with renal parenchymal hypertension09/03/2019
- Different photodegradation behavior of Barnidipine (cas 104757-53-1) under natural and forced irradiation09/02/2019
- Cardiovascular pharmacologyBarnidipine (cas 104757-53-1) ameliorates the vascular and renal injury in l-NAME-induced hypertensive rats09/01/2019
- Cardiovascular pharmacologyPerindopril and Barnidipine (cas 104757-53-1) alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients08/31/2019